Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries

Journal of Cardiovascular Pharmacology

Volumn 55, Issue 5, 2010, Pages 518-521

  Lynch Jr , Joseph J ^a   Regan, Christopher P ^a   Edvinsson, Lars ^b   Hargreaves, Richard J ^c   Kane, Stefanie A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b LUND UNIVERSITY   (Sweden)

^c Neuroscience Administration   (Sweden)

Author keywords

Coronary artery; Telcagepant; Zolmitriptan

Indexed keywords

ALPHA CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; POTASSIUM CHLORIDE; TELCAGEPANT; ZOLMITRIPTAN;

ADULT; ARTERY TONE; ARTICLE; CADAVER; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY CONSTRICTION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; SMOOTH MUSCLE CONTRACTILITY; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ADULT; AZEPINES; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMIDAZOLES; MIDDLE AGED; MIGRAINE DISORDERS; OXAZOLIDINONES; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; TRYPTAMINES; VASOCONSTRICTION; VASODILATION; VASODILATOR AGENTS;

EID: 77952979510     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181d7665f     Document Type: Article

References (15)

1. MaassenVanDenBrink A, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. 1998;98:25-30.
2. Olesen J, Diener H-C, Husstedt I-W. Calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS is effective in the treatment of migraine attacks. N Eng J Med. 2004;350:1104-1110.
3. Ho TW, Mannix LK, Fan X, et al; on behalf of the MK-0974 Protocol 004 Study Group. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008;70:1304-1320.
4. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomized, placebo-controlled, parallel-treatment trial. Lancet. 2008;372:2115-2123.
5. Connor KM, Shapiro RE, Diener H-C, et al. Randomized controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009;73:970-977.
6. Salvatore CA, Hershey JC, Corcoran HA, et al. Pharmacological characterization of MK-0974 [N-[(3R, 6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2- trifluoroethyl) azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b] pyridine-1-yl) piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther. 2008;324:416-421.
7. Martin GR, Robertson AD, MacLennan SJ, et al. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol. 1997;121:157-164.
8. Nilsson T, Longmore J, Shaw D, et al. Characterization of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol. 1999;372:49-56.
9. Peck RW, Seaber EJ, Dixon RM, et al. The pharmacodynamics and pharmacokinetics of the 5HT1B/1D agonist zolmitriptan in healthy young and elderly men and women. Clin Pharmacol Ther. 1998;63:342-353.
10. Dixon R, Engleman K, Kemp J, et al. A comparison of the pharmacokinetics and tolerability of the novel antimigraine compound zolmitriptan in adolescents and adults. J Child Adolesc Psychopharmacol. 1999;9:35-42.
11. Chen X, Liu D, Luan Y, et al. Determination of zolmitriptan in human plasma by liquid chromatography-tandem mass spectrometry method: application to a pharmacodynamic study. J Chromatogr B. 2006;822:30-35. (Pubitemid 43213006)
12. Han TH, Blanchard RL, Palcza J, et al. The pharmacokinetics, safety and tolerability of telcagepant, a novel calcitonin gene-related peptide (CGRP) receptor antagonist, in healthy subjects and migraineurs [abstract]. Clin Pharmacol Ther. 2009; 85: S39-S40.
13. Dixon R, Warrander A. The clinical pharmacokinetics of zolmitriptan. 1997; 17 (Suppl 18) : 15-20.
14. Roller S, Cui D, Laspina C, et al. Preclinical pharmacokinetics of MK-0974, an orally active calcitonin gene-related peptide (CGRP)-receptor antagonist, mechanism of dose dependency and species differences. Xenobiotica. 2009;39:33-45.
15. Chan KY, Edvinsson L, Eftekhari S, et al. Characterization of the CGRP receptor antagonist telcagepant in human isolated coronary artery of different caliber [abstract]. Cephalalgia. 2009;29:1358-1359.